Publications
Detailed Information
T-Cell-Derived Nanovesicles for Cancer Immunotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Jihye | - |
dc.contributor.author | Kang, Mikyung | - |
dc.contributor.author | Jung, Mungyo | - |
dc.contributor.author | Lee, Yun Young | - |
dc.contributor.author | Cho, Yongbum | - |
dc.contributor.author | Kim, Cheesue | - |
dc.contributor.author | Song, Seuk Young | - |
dc.contributor.author | Park, Chun Gwon | - |
dc.contributor.author | Doh, Junsang | - |
dc.contributor.author | Kim, Byung-Soo | - |
dc.date.accessioned | 2024-05-16T01:21:27Z | - |
dc.date.available | 2024-05-16T01:21:27Z | - |
dc.date.created | 2021-07-30 | - |
dc.date.created | 2021-07-30 | - |
dc.date.created | 2021-07-30 | - |
dc.date.issued | 2021-08 | - |
dc.identifier.citation | Advanced Materials, Vol.33 No.33, p. 2101110 | - |
dc.identifier.issn | 0935-9648 | - |
dc.identifier.uri | https://hdl.handle.net/10371/202453 | - |
dc.description.abstract | Although T-cell therapy is a remarkable breakthrough in cancer immunotherapy, the therapeutic efficacy is limited for solid tumors. A major cause of the low efficacy is T-cell exhaustion by immunosuppressive mechanisms of solid tumors, which are mainly mediated by programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-beta). Herein, T-cell-derived nanovesicles (TCNVs) produced by the serial extrusion of cytotoxic T cells through membranes with micro-/nanosized pores that inhibit T-cell exhaustion and exhibit antitumoral activity maintained in the immunosuppressive tumor microenvironment (TME) are presented. TCNVs, which have programmed cell death protein 1 and TGF-beta receptor on their surface, block PD-L1 on cancer cells and scavenge TGF-beta in the immunosuppressive TME, thereby preventing cytotoxic-T-cell exhaustion. In addition, TCNVs directly kill cancer cells via granzyme B delivery. TCNVs successfully suppress tumor growth in syngeneic-solid-tumor-bearing mice. Taken together, TCNV offers an effective cancer immunotherapy strategy to overcome the tumor's immunosuppressive mechanisms. | - |
dc.language | 영어 | - |
dc.publisher | WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim | - |
dc.title | T-Cell-Derived Nanovesicles for Cancer Immunotherapy | - |
dc.type | Article | - |
dc.identifier.doi | 10.1002/adma.202101110 | - |
dc.citation.journaltitle | Advanced Materials | - |
dc.identifier.wosid | 000670512600001 | - |
dc.identifier.scopusid | 2-s2.0-85109389123 | - |
dc.citation.number | 33 | - |
dc.citation.startpage | 2101110 | - |
dc.citation.volume | 33 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Doh, Junsang | - |
dc.contributor.affiliatedAuthor | Kim, Byung-Soo | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | IMMUNE CHECKPOINT INHIBITORS | - |
dc.subject.keywordPlus | GRANZYME-B | - |
dc.subject.keywordPlus | ANTI-PD-1 ANTIBODY | - |
dc.subject.keywordPlus | BETA | - |
dc.subject.keywordPlus | ANTIGEN | - |
dc.subject.keywordPlus | SURFACE | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | INDUCTION | - |
dc.subject.keywordPlus | EXOSOMES | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordAuthor | cancer | - |
dc.subject.keywordAuthor | cytotoxic T cells | - |
dc.subject.keywordAuthor | exhaustion | - |
dc.subject.keywordAuthor | immunotherapy | - |
dc.subject.keywordAuthor | nanovesicles | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.